艾伯维 英语是什么意思 - 英语翻译

• abbvie

在 中文 中使用 艾伯维 的示例及其翻译为 英语

艾伯维不承担对其更新的责任。
BEA assumes no obligation to update them.

生物制药公司艾伯维资助了临床试验。
The biopharmaceutical company AbbVie funded the clinical trials.

艾伯维550亿美元收购Shire.
AbbVie's $55 billion proposed acquisition of Shire.

ORILISSA™的批准证明了艾伯维一直致力于解决严重疾病和未满足需求的承诺。
The approval of ORILISSA demonstrates AbbVie's continued commitment to address serious diseases and unmet needs.".

艾伯维一直利用自由现金流开发其它领域的药物。
AbbVie has been using its free cash to develop drugs in other areas.

两家机构将共同合作开发针对由艾伯维确定的实体瘤靶点的T细胞疗法。
The two organizations will work together to develop T-cell therapies directed to solid tumor targets identified by AbbVie.

艾伯维在几个科学重点领域提供10-12周的暑期实习。
AbbVie offers 10-12 week summer internships in several science focus areas.

他指出，艾尔健和艾伯维这两家竞争对手已经获得了与Rimegepant同类新药的批准。
He notes that two competitors- Allergan and AbbVie- have received approval for a new drug in the same class as Rimegepant.

艾伯维将进一步优先配置其肿瘤学管线中的其他开发项目。
The company will move forward prioritizing other development programs within its oncology pipeline.

为了应对这一局面，艾伯维正在努力推进其他产品的发展，尤其是抗癌药Imbruvica和Venclexta。
Though it has years now to prepare for that, AbbVie is working on advancing other products, notably the cancer drugs Imbruvica and Venclexta.

艾伯维的重点则是临床试验、晚期开发，以及将有前景的新药引入市场。
AbbVie is the focus of the clinical trials, advanced development, as well as the promising new drugs to market.

对于NeurocrineBiosciences来说，这次批准也是一个好消息，2010年艾伯维以5.75亿美元的价格从该公司获得这种药物的权利。
The approval is also good news for Neurocrine Biosciences, from which AbbVie in-licensed the drug in 2010 for $575 million.

此外，艾伯维还参与睾丸素替代疗法，并有治疗多发性硬化的药物。
In addition, AbbVie is involved in testosterone-replacement treatments and has drugs for multiple sclerosis.

勃林格殷格翰将继续负责BI655064的研发，而艾伯维有权在达到某些未公开的临床里程碑后进一步推动这个项目。
BI will retain responsibility for further development of BI 655064, and AbbVie may elect to advance the program after completion of certain clinical achievements.

对于艾伯维而言，EP之所以能给出200亿美元的数字，是源于近期来自安进的一份声明。
For AbbVie, the reason why EP was able to give a figure of 20 billion US dollars stemmed from a recent statement from Amgen.

新”雅培实验室将专注于多元化产品，包括医疗器械、诊断设备和营养产品，而艾伯维将作为研究型的药物制造商。
Abbott Laboratories would specialize in diversified products including medical devices, diagnostic equipment and nutrition products, while AbbVie would operate as a research-based pharmaceutical manufacturer.

艾伯维和勃林格殷格翰将共同负责未来的临床研发，并将建立联合指导委员会.
AbbVie and Boehringer Ingelheim will share responsibility for future clinical development and establish a Joint Steering Committee.

法院裁定艾伯维使用虚假诉讼非法保留其对睾酮替代药物AndroGel的垄断权。
The court ruled that AbbVie used sham litigation against generic drug makers to unlawfully maintain its monopoly over the testosterone replacement drug, AndroGel.

艾伯维将拥有独家收购TeneoOne的权利，并领导TNB-383B随后的全球开发和商业化。
AbbVie will hold the exclusive right to acquire TeneoOne and lead subsequent global development and commercialization of TNB-383B.

根据条款，艾伯维将支付鲁宾首笔3000万美元预付款以获得该项目独家授权。
Under the terms of the agreement, AbbVie will pay Lupin an upfront payment of $30 million for an exclusive license to the programme.

自艾伯维发布Viekira药物以来，该公司还推出了成功的Mavyret，它可以在8周内治愈了丙型肝炎。
Since AbbVie released its Viekira drugs, the company has also rolled out the successful Mavyret, which cures hep C in 8 weeks.

展望未来，艾伯维将继续将研发工作重点聚焦于在研和在售的肿瘤学组合中的其他疗法上。
Moving forward, AbbVie will continue to focus research and development efforts on other therapies in its oncology portfolio of investigational and marketed medicines.

艾伯维将独家负责BI655066的商业化运作，而勃林格殷格翰有权在哮喘领域共同推广该化合物。
AbbVie will be solely responsible for commercialization of BI 655066, while Boehringer Ingelheim will retain an option to co-promote the compound in asthma.

同样，2016年9月，艾伯维合作伙伴AiCure宣布了其基于AI的患者监测平台如何在艾伯维II期精神分裂症试验中改善依从性。
Also, in September 2016, Abbvie partner AiCure announced how its AI-based patient monitoring platform improved adherence in an Abbvie phase 2 schizophrenia trial.

艾伯维列出了22项专利是针对各种疾病或治疗方式，14项专利是有关药物制剂，24项专利是针对该药的生产实践，15项属于其它专利。
Abbvie listed 22 patents for various diseases or methods of treatment, 14 on the drug's formulation, 24 on its manufacturing practices, and 15“other” patents.

根据艾伯维的说法，“辉瑞公司将向艾伯维支付特许权使用费，以授权其Humira®专利，并承认许可专利的有效性。
According to AbbVie,“Pfizer will pay royalties to AbbVie for licensing its Humira® patents and acknowledges the validity of the licensed patents.”.

在艾伯维，我们将先进的科学、专业的经验和饱满的激情有机融合，致力于解决复杂且棘手的疾病难题，为人们的生活带去深远影响。
At AbbVie, we combine advanced science, expertise and passion to solve serious health issues and make a remarkable impact on people's lives.